HAG方案治疗急性髓性细胞白血病的临床疗效及对患者预后的影响研究

Study of the Clinical Efficacy and Prognosis of HAG Regimen in the Treatment of Acute Myeloid Leukemia

目的:研究HAG治疗急性髓性细胞白血病(AML)的实施方案及临床价值。方法:将某院2017年1月~2018年12月期间收治的52例AML患者随机分为C组和H组各26例,分别实施CAG治疗方案、HAG治疗方案,对比两组的临床干预成功率、毒副反应发生率及近远期预后。结果:H组临床干预成功率为76.92%,高于C组的50%(P<0.05);H组和C组患者各类型毒副反应发生率的比较,差异均无统计学意义(P>0.05);H组1年、2年内生存率依次为83.33%、71.43%,均高于C组的65.22%、40%(P<0.05)。结论:HAG方案治疗AML的疗效及患者近远期生存率均较CAG方案高,两种方案下患者毒副反应相当。

Objective:To study the implementation plan and clinical value of HAG in the treatment of acute myeloid leukemia(AML).Methods:Fifty-two patients with AML admitted to a hospital from January 2017 to December 2018 were selected and randomly divided into group C(n=26)and group H(n=26),who were treated with CAG treatment regimen and HAG treatment regimen respectively.The success rate of clinical intervention,the incidence of adverse reactions,the short-term and long-term prognosis of the two groups were compared.Results:The success rate of clinical intervention in group H was 76.92%,which was higher than 50%in group C(P<0.05).There was no statistical significance in the incidence of each type of adverse reactions between group H and group C(P>0.05).The 1-year and 2-year survival rates in group H were 83.33%and 71.43%,respectively,which were all higher than those in group C(65.22%and 40%,P<0.05).Conclusion:HAG regimen has higher efficacy and short-term and long-term survival rate in the treatment of AML than CAG regimen,and the toxic and side effects of patients under the two regimens are similar.